Enter a keyword or phrase to search all pages in this section:

Advanced search


Looking for a previously published document in this section?

Class 2 Drug Alert (Action Within 48 Hours): Bydureon 2mg powder and solvent for prolonged-release suspension for injection - Eli Lilly Nederland B.V. (EL (13)A/22)

Document details:

Type: Drug Alert
Series No: EL (13)A/22
Audience: Healthcare professionals 
Published: 16 September 2013
Format: Electronic
Size: A4
Pages: 1
Price: Free
Copyright: Crown

Help viewing PDFs:



Action Within 48 Hours

Pharmacy, Clinic and Wholesaler Level Recall

16 September 2013 EL (13)A/22 Our ref: 

MDR 14-09/13

Dear Healthcare Professional,

Eli Lilly Nederland B.V.

BYDUREON 2mg powder and solvent for prolonged-release suspension for injection



Batch number

Expiry date

Pack size

First distributed


31 August 2015

4 x 1 single-dose kit
(1 vial + 1 syringe)

12 July 2013

Bristol-Myers Squibb and Astra Zeneca, who, following a recent change of ownership, are now Marketing Authorisation holders for the Bydureon (Exenatide) product licence range, are recalling the above batch of Bydureon to pharmacy, clinic and wholesaler level, following an in-depth review of manufacturing records which indicated that this batch may contain a very small number of under filled vials.  The low fills impact approximately 0.2% of the batch and range between 30% and 75% of the labeled dose.

Remaining stocks of the affected batch should be quarantined and returned to the original supplier for credit.  For enquiries relating to stock returns please contact your original suppliers local service center.

For medical information enquiries please contact BMS by phone on 0800 731 1736 or by email to medical.information@bms.com.

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.

Yours faithfully

Alison Bunce
Pharmaceutical Assessor
Defective Medicines Report Centre
151 Buckingham Palace Road
Telephone +44 (0)20 3080 6574

MHRA Distribution (further recipients by cascade): .
Page last modified: 16 September 2013